530959 Sigma-AldrichTAZ Activity Modulator, TM-25659 - CAS 260553-97-7 - Calbiochem
A cell-permeable enhancer of nuclear localization of transcriptional co-activator with PDZ-binding motif (TAZ). Does not affect the total amount of TAZ in pluripotent C3H10T1/2 cells.
More>> A cell-permeable enhancer of nuclear localization of transcriptional co-activator with PDZ-binding motif (TAZ). Does not affect the total amount of TAZ in pluripotent C3H10T1/2 cells. Less<<Synonymes: TM25659, TM 25659
Produits recommandés
Aperçu
Replacement Information |
---|
Tableau de caractéristiques principal
CAS # | Empirical Formula |
---|---|
260553-97-7 | C₃₀H₂₈N₈ |
Prix & Disponibilité
Référence | Disponibilité | Conditionnement | Qté | Prix | Quantité | |
---|---|---|---|---|---|---|
5309590001 |
|
Flacon en verre | 5 mg |
|
— |
References | |
---|---|
References | Jang, E.J., et al. 2012. Br. J. Pharmacol. 165, 1584. |
Product Information | |
---|---|
CAS number | 260553-97-7 |
Form | Yellow powder |
Hill Formula | C₃₀H₂₈N₈ |
Chemical formula | C₃₀H₂₈N₈ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Purity | ≥97% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Référence | GTIN |
5309590001 | 04055977283259 |
Documentation
TAZ Activity Modulator, TM-25659 - CAS 260553-97-7 - Calbiochem FDS
Titre |
---|
Références bibliographiques
Aperçu de la référence bibliographique |
---|
Jang, E.J., et al. 2012. Br. J. Pharmacol. 165, 1584. |
Informations techniques
Titre |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |